1. Home
  2. News
  3. News
  4. Apply to TFDA for IND of AD17002-SC for the treatment of phase II human clinical trials in patients with mild COVID-19.

Apply to TFDA for IND of AD17002-SC for the treatment of phase II human clinical trials in patients with mild COVID-19.

Apply to TFDA for IND of AD17002-SC for the treatment of phase II human clinical trials in patients with mild COVID-19.
2021-05-10
Back
繁體中文
English
简体中文
This site uses cookies to collect the necessary user browsing behavior so that we can provide you with a better browsing experience. Browse this site, which means you agree with "online privacy declaration."